Literature DB >> 9063015

Biological behaviour of moderate dysplasia--a prospective study.

N S Murthy1, S Sardana, N Narang, S S Agarwal, S Sharma, D K Das.   

Abstract

The present communication reports the biological behaviour of women with moderate dysplastic lesions of uterine cervix based on a long term prospective study. Two hundred and thirty nine women with moderate dysplasia by cervical cytology who satisfied the criteria for registration were longitudinally followed up at 3 +/- 1 monthly intervals along with age and parity matched controls for a period ranging from 4 to 132 months. The cumulative rate of progression from moderate dysplasia to malignancy (CIS) was observed to be 23.0% at the end of 72 months of follow up with mean transition interval of 24.2 months. Out of 239 cases, 142 women who had more than 24 months of follow up were considered for studying the biological behaviour of the lesion. It was observed that during a follow up of 132 months, 14(9.9%) and 15(10.6%) women progressed to carcinoma in-situ and severe dysplasia respectively. The persistence of lesion was observed in 21(14.8%) women while 11(7.3%) and 81(57.0%) regressed to mild dysplasia and normalcy respectively.

Entities:  

Mesh:

Year:  1996        PMID: 9063015

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  2 in total

1.  Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

Authors:  Tomoko Matsumoto; Naoki Matsumaru; Paul Scuffham; Pieter Neels; Katsura Tsukamoto
Journal:  Ther Innov Regul Sci       Date:  2020-06-22       Impact factor: 1.778

2.  HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.

Authors:  J K Chan; B J Monk; C Brewer; K A Keefe; K Osann; S McMeekin; G S Rose; M Youssef; S P Wilczynski; F L Meyskens; M L Berman
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.